HCG17: A Potential Drug Target and Biomarker (G414778)

Target Name: HCG17

NCBI ID: G414778

HCG17

Other Name(s): HLA complex group 17 | HCG18 | LINC00046 | NCRNA00046

HCG17: A Potential Drug Target and Biomarker

Human chorionic gonadotropin (HCG) is a hormone produced by the placenta after fertilization occurs. It is a small, simple protein with a molecular weight of approximately 60,000 daltons. Despite its small size, HCG has a profound impact on fetal development and growth.HCG17, a subtype of HCG, has been identified as a potential drug target and biomarker for several diseases.

HCG17 is a member of the HLA complex group 17, which is one of the major histocompatibility complex (MHC) regions. The HLA complex is a genetic immune system that plays a critical role in the immune response. It is composed of several subtypes, including HLA-A, HLA-B, HLA-C, and HLA-D. These subtypes are responsible for presenting antigens from the body's immune system to the immune system, and for coordinating the immune response to those antigens.

HCG17 is a 17-kDa protein that is expressed in a variety of tissues, including the placenta, spleen, lung, liver, and thymus. It is primarily produced by the placenta, and its levels in the body are low. However, its presence is detectable in the urine and feces of pregnant women, and its levels can be used as a marker for pregnancy.

One of the reasons why HCG17 has potential as a drug target is its role in cancer development. Several studies have shown that high levels of HCG17 are associated with the development of several types of cancer, including urinary tract cancer, cervical cancer, and breast cancer. Additionally, HCG17 has been shown to promote the growth and survival of cancer cells, which may make it an attractive target for cancer treatment.

Another potential drug target for HCG17 is its role in autoimmune diseases. HCG17 is involved in the development and maintenance of the immune system, and has been shown to contribute to the development of autoimmune diseases. For example, studies have shown that HCG17 is involved in the development of rheumatoid arthritis, a type of autoimmune disease. Additionally, HCG17 has been shown to contribute to the development of multiple sclerosis, another autoimmune disease.

HCG17 may also be a potential biomarker for some types of neurodegenerative diseases. The neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. HCG17 has been shown to be involved in the development and progression of neurodegenerative diseases, and may be a useful biomarker for these conditions.

In addition to its potential as a drug target and biomarker, HCG17 is also of interest as a potential vaccine. HCG17 is a glycoprotein that is found on the surface of many immune cells, including dendritic cells, macrophages, and B cells. This makes it an attractive target for a vaccine that can stimulate an immune response against cancer cells and other infected particles.

Overall, HCG17 is a protein that has the potential to be a drug target and biomarker for several diseases. Further research is needed to fully understand its role in the immune system and its potential as a vaccine.

Protein Name: HLA Complex Group 17

The "HCG17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HCG17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets